Recent Progress on Therapeutic Vaccines for Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jun 23

PMID 35734599

Authors

Lianru Zhang

Xipeng Zhou

Huizi Sha

Li Xie

Baorui Liu

Affiliations

Soon will be listed here.

Abstract

Breast cancer remains the most frequently diagnosed malignancy worldwide. Advanced breast cancer is still an incurable disease mainly because of its heterogeneity and limited immunogenicity. The great success of cancer immunotherapy is paving the way for a new era in cancer treatment, and therapeutic cancer vaccination is an area of interest. Vaccine targets include tumor-associated antigens and tumor-specific antigens. Immune responses differ in different vaccine delivery platforms. Next-generation sequencing technologies and computational analysis have recently made personalized vaccination possible. However, only a few cases benefiting from neoantigen-based treatment have been reported in breast cancer, and more attention has been given to overexpressed antigen-based treatment, especially human epidermal growth factor 2-derived peptide vaccines. Here, we discuss recent advancements in therapeutic vaccines for breast cancer and highlight near-term opportunities for moving forward.

Citing Articles

Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy.

Ye J, Wang H, Chakraborty S, Sang X, Xue Q, Sun M Int J Mol Sci. 2025; 26(3).

PMID: 39941108 PMC: 11818183. DOI: 10.3390/ijms26031340.

Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.

Montero-Calle A, Garranzo-Asensio M, Moreno-Casbas M, Campuzano S, Barderas R Front Immunol. 2024; 15:1455602.

PMID: 39234247 PMC: 11371560. DOI: 10.3389/fimmu.2024.1455602.

Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells.

Sanchez-Leon M, Jimenez-Cortegana C, Silva Romeiro S, Garnacho C, de la Cruz-Merino L, Garcia-Dominguez D Int J Mol Sci. 2023; 24(6).

PMID: 36982282 PMC: 10048951. DOI: 10.3390/ijms24065208.

Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance.

Azam A, Sounni N Cancers (Basel). 2022; 14(24).

PMID: 36551752 PMC: 9776509. DOI: 10.3390/cancers14246267.

References

Pierce R, Campbell J, Pai S, Brody J, Kohrt H . In-situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccin Immunother. 2015; 11(8):1901-9. PMC: 4635874. DOI: 10.1080/21645515.2015.1049779. View

Yokoi T, Oba T, Kajihara R, Abrams S, Ito F . Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Sci Rep. 2021; 11(1):21992. PMC: 8578367. DOI: 10.1038/s41598-021-01455-4. View

Liu W, Tang H, Li L, Wang X, Yu Z, Li J . Peptide-based therapeutic cancer vaccine: Current trends in clinical application. Cell Prolif. 2021; 54(5):e13025. PMC: 8088465. DOI: 10.1111/cpr.13025. View

Obst R, van Santen H, Melamed R, Kamphorst A, Benoist C, Mathis D . Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. Proc Natl Acad Sci U S A. 2007; 104(39):15460-5. PMC: 2000557. DOI: 10.1073/pnas.0707331104. View

Carmichael M, Benavides L, Holmes J, Gates J, Mittendorf E, Ponniah S . Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2009; 116(2):292-301. DOI: 10.1002/cncr.24756. View

Zhang P, Yi S, Li X, Liu R, Jiang H, Huang Z . Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells. PLoS One. 2014; 9(7):e102197. PMC: 4103844. DOI: 10.1371/journal.pone.0102197. View

Grimaldi A, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V . Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014; 3:e28780. PMC: 4106166. DOI: 10.4161/onci.28780. View

Mohebtash M, Tsang K, Madan R, Huen N, Poole D, Jochems C . A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011; 17(22):7164-73. PMC: 3227395. DOI: 10.1158/1078-0432.CCR-11-0649. View

Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli M . Dendritic cell-based vaccines: clinical applications in breast cancer. Immunotherapy. 2014; 6(3):349-60. DOI: 10.2217/imt.13.169. View

10.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

11.

Lopes A, Bastiancich C, Bausart M, Ligot S, Lambricht L, Vanvarenberg K . New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models. J Immunother Cancer. 2021; 9(4). PMC: 8021892. DOI: 10.1136/jitc-2020-001243. View

12.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

13.

Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H . Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004; 101(38):13885-90. PMC: 518848. DOI: 10.1073/pnas.0405884101. View

14.

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539-43. PMC: 46336. DOI: 10.1073/pnas.90.8.3539. View

15.

Kinney A, Sahin A, Vernon S, Frankowski R, Annegers J, Hortobagyi G . The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer. 1997; 80(12):2240-9. DOI: 10.1002/(sici)1097-0142(19971215)80:12<2240::aid-cncr4>3.0.co;2-y. View

16.

Hwang S, Kim E, Lee I, Marcotte E . Systematic comparison of variant calling pipelines using gold standard personal exome variants. Sci Rep. 2015; 5:17875. PMC: 4671096. DOI: 10.1038/srep17875. View

17.

Vassilaros S, Tsibanis A, Tsikkinis A, Pietersz G, McKenzie I, Apostolopoulos V . Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy. 2013; 5(11):1177-82. DOI: 10.2217/imt.13.126. View

18.

Egland K, Kumar V, Duray P, Pastan I . Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther. 2002; 1(7):441-50. View

19.

Miles D, Roche H, Martin M, Perren T, Cameron D, Glaspy J . Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. PMC: 3228158. DOI: 10.1634/theoncologist.2010-0307. View

20.

Tsang K, Zaremba S, Nieroda C, Zhu M, HAMILTON J, Schlom J . Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995; 87(13):982-90. DOI: 10.1093/jnci/87.13.982. View